<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">482</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2016-12-1-36-41</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыря</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Late results of treatment and quality of life in women after pelvic exenteration</article-title><trans-title-group xml:lang="ru"><trans-title>Поздние результаты лечения и качество жизни после экзентерации органов таза у женщин</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Loran</surname><given-names>O. B.</given-names></name><name xml:lang="ru"><surname>Лоран</surname><given-names>О. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Urology and Surgical Andrology, </p><p>5, Second Botkinsky Passage, Build. 16, Moscow 125284</p></bio><bio xml:lang="ru"><p>Кафедра урологии и хирургической андрологии,</p><p>125284, Москва, 2-й Боткинский проезд, 5, корп. 16</p></bio><email>oleg_loran@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Seregin</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Серегин</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Urology and Surgical Andrology, </p><p>5, Second Botkinsky Passage, Build. 16, Moscow 125284</p></bio><bio xml:lang="ru"><p>Кафедра урологии и хирургической андрологии,</p><p>125284, Москва, 2-й Боткинский проезд, 5, корп. 16</p></bio><email>41urology@41urology.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dovlatov</surname><given-names>Z. A.</given-names></name><name xml:lang="ru"><surname>Довлатов</surname><given-names>З. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>5, Second Botkinsky Passage, Build. 16, Moscow 125284</p></bio><bio xml:lang="ru"><p>125284, Москва, 2-й Боткинский проезд, 5, корп. 16</p></bio><email>dovlatov.zyaka@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Postgraduate Education</institution></aff><aff><institution xml:lang="ru">РМАПО</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">S.P. Botkin City Clinical Hospital</institution></aff><aff><institution xml:lang="ru">Городская клиническая больница им. С.П. Боткина</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-03-30" publication-format="electronic"><day>30</day><month>03</month><year>2016</year></pub-date><volume>12</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>36</fpage><lpage>41</lpage><history><date date-type="received" iso-8601-date="2015-09-16"><day>16</day><month>09</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-12-08"><day>08</day><month>12</month><year>2015</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/482">https://oncourology.abvpress.ru/oncur/article/view/482</self-uri><abstract xml:lang="en"><p><bold>Objective:</bold> to study the late results and quality of life in women after pelvic exenteration.</p><p><bold>Subjects and methods.</bold> The late results of surgery and quality of life were studied using the SF-36 questionnaire in 45 women with bladder cancer and in 47 with cervical cancer at follow-ups of 3-104 months (median 51 months) after pelvic exenteration.</p><p><bold>Results.</bold> The five-year overall and relapse-free survival rates were 60.9±15.8 and 55.4±12.6%, respectively. All quality of life indicators virtually improved as compared to preoperative data.</p><p><bold>Conclusion.</bold> Pelvic exenteration at a reference center allows patients to achieve rather high survival rates and quality of life.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования –</bold> изучение отдаленных результатов и качества жизни после экзентерации органов таза у женщин.</p><p><bold>Материалы и методы.</bold> При сроках наблюдения после экзентерации органов таза 3–104 мес (медиана – 51 мес) у 45 женщин по поводу рака мочевого пузыря и 47 – по поводу рака шейки матки изучены отдаленные результаты операции и качество жизни с помощью анкеты SF-36.</p><p><bold>Результаты.</bold> Пятилетняя общая и безрецидивная выживаемость больных составила 60,9 ± 15,8 и 55,4 ± 12,6 % соответственно. Качество жизни по сравнению с дооперационными данными практически по всем параметрам улучшилось.</p><p><bold>Заключение.</bold> Выполнение экзентерации тазовых органов в условиях референс-центра позволяет добиться достаточно высоких показателей выживаемости и качества жизни больных.</p></trans-abstract><kwd-group xml:lang="en"><kwd>pelvic exenteration</kwd><kwd>bladder cancer</kwd><kwd>cervical cancer</kwd><kwd>survival</kwd><kwd>quality of life</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>экзентерация органов таза</kwd><kwd>рак мочевого пузыря</kwd><kwd>рак шейки матки</kwd><kwd>выживаемость</kwd><kwd>качество жизни</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. 250 с. [Malignant tumors in Russia in 2013 (morbidity and fatality). Ed. by А.D. Kaprin, V.V. Starinsky, G.V. Petrova. М., 2015. 250 с. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. 250 с. [Malignant tumors in Russia in 2013 (morbidity and fatality). Ed. by А.D. Kaprin, V.V. Starinsky, G.V. Petrova. М., 2015. 250 с. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Состояние онкологической помощи населению России в 2013 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2014. 235 с. [Status of cancer care facilities, provided to the population of Russia in 2013. Ed. by А.D. Kaprin, V.V. Starinsky, G.V. Petrova. М., 2015. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2013 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2014. 235 с. [Status of cancer care facilities, provided to the population of Russia in 2013. Ed. by А.D. Kaprin, V.V. Starinsky, G.V. Petrova. М., 2015. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Косенко И.А., Матылевич О.П. Экзентерация таза у больных раком шейки матки: обзор литературы. Онкологический журнал 2008;2(4):82–9. [Коsenkо I.А., Маtylevich О.P. Pelvis exenteration at patients with cervical cancer: literature review. Onkologicheskiy zhurnal = Оncologic Magazine 2008;2(4): 82–9. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Косенко И.А., Матылевич О.П. Экзентерация таза у больных раком шейки матки: обзор литературы. Онкологический журнал 2008;2(4):82–9. [Коsenkо I.А., Маtylevich О.P. Pelvis exenteration at patients with cervical cancer: literature review. Onkologicheskiy zhurnal = Оncologic Magazine 2008;2(4): 82–9. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Diver E.J., Rauh-Hain J.A., Del Carmen M.G. Total pelvic exenteration for gynecologic malignancies. Int J Surg Oncol 2012. URL:</mixed-citation><mixed-citation xml:lang="ru">Diver E.J., Rauh-Hain J.A., Del Carmen M.G. Total pelvic exenteration for gynecologic malignancies. Int J Surg Oncol 2012. URL:</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376473 (Дата обращения: 20.02.2015).</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">5. Dresen R., Gosens M., Martijn H. et al. Radical resection after IORT-containing multimodality treatment is the most important determinant of outcome in patients treated for LRRC. Ann Surg Oncol 2008;15(7):1937–47.</mixed-citation><mixed-citation xml:lang="ru">Dresen R., Gosens M., Martijn H. et al. Radical resection after IORT-containing multimodality treatment is the most important determinant of outcome in patients treated for LRRC. Ann Surg Oncol 2008;15(7):1937–47.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">6. Ferenschild F., Vermaas M., Verhoef C. et al. Total pelvic exenteration for primary and recurrent malignancies. World J Surg 2009; 33(7):1502–8.</mixed-citation><mixed-citation xml:lang="ru">Ferenschild F., Vermaas M., Verhoef C. et al. Total pelvic exenteration for primary and recurrent malignancies. World J Surg 2009; 33(7):1502–8.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">7. Austin K.K., Young J.M., Solomon M.J. Quality of life of survivors after pelvic exenteration for rectal cancer. Dis Colon Rectum 2010;53(8):1121–6.</mixed-citation><mixed-citation xml:lang="ru">Austin K.K., Young J.M., Solomon M.J. Quality of life of survivors after pelvic exenteration for rectal cancer. Dis Colon Rectum 2010;53(8):1121–6.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">8. Dindo D., Demartines N., Clavien P.A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240(2):205–13.</mixed-citation><mixed-citation xml:lang="ru">Dindo D., Demartines N., Clavien P.A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240(2):205–13.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">9. Yoo H.J., Lim M.C., Seo S.S. et al. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. J Gynecol Oncol 2012;23(4):242–50.</mixed-citation><mixed-citation xml:lang="ru">Yoo H.J., Lim M.C., Seo S.S. et al. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. J Gynecol Oncol 2012;23(4):242–50.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">10. Ramamurthy R., Duraipandian A. Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignancies. Indian J Surg Oncol 2012;3(3):231–5.</mixed-citation><mixed-citation xml:lang="ru">Ramamurthy R., Duraipandian A. Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignancies. Indian J Surg Oncol 2012;3(3):231–5.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">11. Kim J. Pelvic exenteration: surgical approaches. J Korean Soc Coloproctol 2012;28(6):286–93.</mixed-citation><mixed-citation xml:lang="ru">Kim J. Pelvic exenteration: surgical approaches. J Korean Soc Coloproctol 2012;28(6):286–93.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">12. Goldberg G.L., Sukumvanich P., Einstein M.H. et al. Total pelvic exenteration: the Albert Einstein College of Medicine/ Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol 2006;101(2):261–8.</mixed-citation><mixed-citation xml:lang="ru">Goldberg G.L., Sukumvanich P., Einstein M.H. et al. Total pelvic exenteration: the Albert Einstein College of Medicine/ Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol 2006;101(2):261–8.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">13. Ishiguro S., Akasu T., Fujita S. et al. Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period. Surgery 2009:145(2): 189–95.</mixed-citation><mixed-citation xml:lang="ru">Ishiguro S., Akasu T., Fujita S. et al. Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period. Surgery 2009:145(2): 189–95.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">14. Матылевич О.П., Косенко И.А., Красный С.А. и др. Ближайшие результаты экзентерации таза у больных раком шейки матки. Онкологический журнал 2010;4(1):22–7. [Маtylevich О.P., Kosenkо I.А., Krasny S.А. et al. Recent results of pelvis exenteratopn and patients with cervical cancer. Onkologicheskiy zhurnal = Оncologic Magazine 2010;4(1):22–7. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Матылевич О.П., Косенко И.А., Красный С.А. и др. Ближайшие результаты экзентерации таза у больных раком шейки матки. Онкологический журнал 2010;4(1):22–7. [Маtylevich О.P., Kosenkо I.А., Krasny S.А. et al. Recent results of pelvis exenteratopn and patients with cervical cancer. Onkologicheskiy zhurnal = Оncologic Magazine 2010;4(1):22–7. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">15. Дронов А.И., Крючина Е.А., Горлач А.И., Добуш Р.Д. Экзентерация таза в лечении первичных и рецидивных злокачественных опухолей. Шпитальна хiрургiя 2013;1:111–3. [Dronov А.I., Kruchinа Е.А., Gorlach А.I., Dobush R.D. Pelvis exenteration in the treatment of initial and recurrent malignant tumors. Шпитальна хiрургiя 2013;1:111–3. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Дронов А.И., Крючина Е.А., Горлач А.И., Добуш Р.Д. Экзентерация таза в лечении первичных и рецидивных злокачественных опухолей. Шпитальна хiрургiя 2013;1:111–3. [Dronov А.I., Kruchinа Е.А., Gorlach А.I., Dobush R.D. Pelvis exenteration in the treatment of initial and recurrent malignant tumors. Шпитальна хiрургiя 2013;1:111–3. (In Russ.)].</mixed-citation></citation-alternatives></ref></ref-list></back></article>
